Cargando…

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer

Breast cancer (BC) is caused by epigenetic modifications and genetic heterogeneity and exhibits various histological feature. HER2+ (Human epidermal growth factor receptor 2) is a more aggressive type of breast cancer, diagnosis and prognosis are difficult for HER2+ BC. Anti-HER2+ inhibitors have be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Desh Deepak, Lee, Hae-Jeung, Yadav, Dharmendra Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792097/ https://www.ncbi.nlm.nih.gov/pubmed/36578543 http://dx.doi.org/10.3389/fphar.2022.1089066

Ejemplares similares

Recent Clinical Advances on Long Non-Coding RNAs in Triple-Negative Breast Cancer
por: Singh, Desh Deepak, et al.
Publicado: (2023)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors
por: Singh, Desh Deepak, et al.
Publicado: (2023)

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
por: Yang, Xue, et al.
Publicado: (2020)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Schlam, Ilana, et al.
Publicado: (2021)

Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2
por: Wang, Bo-Wei, et al.
Publicado: (2021)

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
por: Singh, Desh Deepak, et al.
Publicado: (2021)

TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy
por: Singh, Desh Deepak, et al.
Publicado: (2021)

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer
por: Deepak Singh, Desh, et al.
Publicado: (2021)

SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
por: Singh, Desh Deepak, et al.
Publicado: (2021)

Corrigendum: SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Frankincense oil-loaded nanoemulsion formulation of paclitaxel and erucin: A synergistic combination for ameliorating drug resistance in breast cancer: In vitro and in vivo study
por: Kaur, Harneetpal, et al.
Publicado: (2022)

Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?
por: Ursini-Siegel, Josie
Publicado: (2013)

Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2020)

Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors
por: Shim, Jaehee V., et al.
Publicado: (2023)

Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors
por: Futosi, Krisztina, et al.
Publicado: (2023)

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
por: Paech, Franziska, et al.
Publicado: (2017)

Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential
por: Rivera-Torres, José, et al.
Publicado: (2019)

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
por: Wang, Kun, et al.
Publicado: (2021)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases
por: Singh, Desh Deepak, et al.
Publicado: (2023)

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
por: Liu, Yihan, et al.
Publicado: (2022)

Tyrosine kinase inhibitors in HER2‐positive breast cancer brain metastases: A systematic review and meta‐analysis
por: Yu, Yushuai, et al.
Publicado: (2023)

Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection
por: Climent, Núria, et al.
Publicado: (2019)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials
por: Qu, Kai, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update
por: Naik, Rajashri R., et al.
Publicado: (2023)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2
por: Singh, Desh Deepak, et al.
Publicado: (2020)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021)

Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer
por: Jiang, Huafeng, et al.
Publicado: (2023)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
por: Griffin, Nathan, et al.
Publicado: (2020)

Editorial: Kinase inhibitors in cancer therapy
por: Yadav, Dharmendra Kumar
Publicado: (2022)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1lt9q0p55sru1hvs98e58h4ts6